Request an invite

Kimmtrak: genotox, carcinogenicity and repro: done or skipped?

tebentafusp · CD3 x gp100 (TCR fusion)
Genotoxicity
Not conducted (fusion protein; ICH S6/S9)
“Based on the biologic properties of tebentafusp, a fusion protein, genetic toxicology studies are not warranted.”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗
Carcinogenicity
Not conducted (advanced cancer indication)
“Carcinogenicity studies were not warranted for the proposed indication.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Reproductive & developmental
Not conducted (no relevant species); weight-of-evidence; FDA concluded possible fetal harm to skin, inner ear, eye
“Due to the specificity for human targets, embryo-fetal development (EFD) studies cannot be conducted in nonclinical species. Therefore, a weight of evidence assessment was conducted to evaluate the risk of tebentafusp administration on pregnancy and embryo-fetal development.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Safety pharmacology
Not conducted (no relevant species; in vitro only)
“Therefore, no specific safety pharmacology studies were conducted.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗

Same question, other bispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Not conducted (ICH S6(R1))

Blincyto

blinatumomab · CD19 x CD3
Not conducted (ICH S6(R1); protein of natural amino acids)

Columvi

glofitamab · CD20 x CD3
Not conducted (ICH S6(R1))

Elrexfio

elranatamab · BCMA x CD3
Not conducted (ICH S6(R1))

Epkinly

epcoritamab · CD20 x CD3
Not conducted (ICH S6(R1), ICH S9)

Hemlibra

emicizumab · FIXa x FX
Not conducted (ICH S6)

Imdelltra

tarlatamab · DLL3 x CD3
Not conducted (ICH S6(R1))

Korjuny

catumaxomab · EpCAM x CD3
Not conducted (ICH S6(R1))

Lunsumio

mosunetuzumab · CD20 x CD3
Not conducted (ICH S6(R1))

Lynozyfic

linvoseltamab · BCMA x CD3
Not conducted (antibody not expected to interact with DNA)

Ordspono

odronextamab · CD20 x CD3
Not conducted (antibody not expected to interact with DNA)

Removab

catumaxomab · EpCAM x CD3
Not conducted (not submitted; biologic, no relevant model)

Rybrevant

amivantamab · EGFR x MET
Not conducted (not appropriate for antibodies)

Talvey

talquetamab · GPRC5D x CD3
Not conducted (ICH S6; biotechnology-derived product)

Tecvayli

teclistamab · BCMA x CD3
Not conducted (ICH S6(R1))

Vabysmo

faricimab · VEGF-A x Ang-2
Not conducted (ICH S6(R1))

Ziihera

zanidatamab · HER2 x HER2 (biparatopic)
Not conducted (ICH S6(R1), ICH S9)

Summary across all 18 bispecifics →